Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Trust-aware, REliable and Distributed Information SEcurity in the Cloud. (TREDISEC)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Spain,Spain,Switzerland,Greece,France,France,United Kingdom
Call: Cybersecurity, Trustworthy ICT (H2020-ICT-2014-1, 2014)
Start date: 2015-04-01
End date: 2018-03-31
Duration (months): 36.0
Total project cost (EUR): 6470618.94
EU funding (EUR): 4412063.0
Participants: 10
Project status: CLOSED

The current trend for data placement shows a steady shift towards "the cloud". The advent of cloud storage and computation services however comes at the expense of data security and user privacy. To remedy this, customers nowadays call for end-to-end security whereby only end-users and authorized parties have access to their data and no-one else. This is especially true after the outbreak of data breaches and global surveillance programs last year. In the TREDISEC project, we address this problem and we develop systems and techniques which make the cloud a secure and efficient heaven to store data. We plan to step away from a myriad of disconnected security protocols or cryptographic algorithms, and to converge on a single framework where all objectives are met. More specifically, TREDISEC addresses the confidentiality and integrity of outsourced data in the presence of a powerful attacker who controls the entire network. In addition, our proposed security primitives support data compression and data deduplication, while providing the necessary means for cloud providers to efficiently search and process encrypted data. By doing so, TREDISEC aims at creating technology that will impact existing businesses and will generate new profitable business opportunities long after the project is concluded.

Keywords: end to end security,access control for multi tenancy,efficient processing and search over encrypted data,confidentiality,integrity,verifiability,proof of ownership,proof of retrievability
Personal Technologies for Affective Health (AffecTech)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Spain,Ireland,Italy,Italy,Australia,Spain,Ireland,Italy,Türkiye,Sweden,Türkiye,Switzerland,Sweden,United States,Netherlands,United Kingdom,United Kingdom,United Kingdom,Portugal,United Kingdom
Call: Innovative Training Networks (H2020-MSCA-ITN-2016, 2016)
Start date: 2017-01-01
End date: 2021-03-31
Duration (months): 51.0
Total project cost (EUR): 3871209.57
EU funding (EUR): 3871209.5700000003
Participants: 25
Project status: CLOSED

Personalized health is a European priority and one of the strategic research areas for Horizon 2020. This project advances the state-of-the-art of personal health technologies for affective disorders, estimated to be the highest ranking cause of disease by 2020. It marks a significant shift from the current wearable technologies capturing emotional responses whose understanding usually requires physicians’ input, to low-cost self-help technologies for visualizing, exploring and regulating emotions. AFFECTIVA integrates the latest Human-Computer Interaction and Biomedical Engineering findings in designing and developing personal health systems for mental health, with the most influential outcomes and models of emotion regulation from Clinical Psychology. The overall aim is to support self-understanding and successful adoption of adaptive emotion regulation strategies in daily life. AFFECTIVA will contribute towards four significant outcomes: (1) wearable systems for capturing emotion regulation, (2) applications for understanding emotions and their regulatory processes, (3) interactive tools for training adaptive emotion regulation strategies, and (4) theoretical contributions to emotion regulation research in real life. AFFECTIVA builds on exceptional European and North American expertise from both academic and private sector to provide personalized health research with a timely and much needed momentum to address the pressing social challenge of emotional wellbeing and health.

Keywords: affective health technologies,wearables,biosensors,emotion regulation
Labmaster Lucia - revolutionizing blood diagnostics with rapid accurate low-cost point-of-care tests (LABMASTER LUCIA)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Active ageing and self-management of health
Action type: SME instrument
Countries involved: Finland
Call: Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2018-02-01
End date: 2018-05-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The Labmaster Lucia is the next generation diagnostics instrument for point-of-care blood tests. The compact device harnesses the breakthrough Cathodic ElectroChemiLuminescence (CECL) method to increase diagnostic speed and precision. Using the Lucia, medical staff can perform in vitro diagnostics (IVD) anywhere and get accurate results within five minutes at a fraction of the cost of existing methods. Blood diagnostics are critical for patient treatment, but current options are slow and costly due to large IVD immobile equipment. IVD devices are hard to miniaturize due to the scientific problem of sample medium signal interference. Labmaster's patented CECL technology overcomes signal disturbance problems using hydrated hot electrons that bypass fluid media, enabling the creation of small, mobile IVD devices for fast on-site diagnostics. Using CECL, Labmaster has created two products: (1) The Lucia, a 2kg POC IVD unit; (2) Test cartridges with antibodies to test a range of medical conditions. The Lucia improves on current FI and AECL IVD methods which require large expensive laboratory equipment, or have limited testing ranges. The Lucia has a wider testing range and allows simultaneous tests on one cartridge. It will be priced 50% below the current segment leader. This will reduce public health spending, improve treatment and lessen antibiotic prescription. The Lucia and cartridges will be sold to hospitals and clinics in Europe and Asia via medtech distributors. One Asian distributor is secured, six more will be targetted in this project. Labmaster Oy was founded in Finland in 1985, has 17 expert staff, and already commercialized 16 diagnostic innovations. It aims to sell 23,000 Lucia instruments and 10M cartridges by 2023, generating €291M in revenue. This project will prepare for the development of a new cartridge to test for a common condition, and prepare for commercialisation.

Keywords: diagnostics,medtech
The role of CD63 in lysosomal degradation of insulin granules in pancreatic beta cells in T2D diabetes (INSULYSOSOME)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: France
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-11-01
End date: 2020-10-31
Duration (months): 24.0
Total project cost (EUR): 173076.0
EU funding (EUR): 173076.0
Participants: 1
Project status: CLOSED

The pancreatic β cell harbors an exemplary nutrient sensing machinery that is coupled to secretion of insulin. While mechanisms governing regulation of insulin secretion in response to nutrients were widely investigated, little is known about how nutrients impact on other basic cellular processes such as insulin granule turnover, autophagy and cellular growth, deregulation of all of which have been demonstrated to be involved in β cell failure in type 2 diabetes (T2D). T2D represents a major health burden accounting for a large part of exploding health costs world-wide. Restoring normal weight through exercise and decreased food consumption in principle is straight-forward to mitigate metabolic disturbances. However, changing the sedentary life style is very challenging for obese subjects and that at a late disease stage, β cell failure becomes irreversible. There is an emerging endeavor of the pharmaceutical industry to develop strategies targeting the β cell that go beyond improving insulin secretion. A prevailing concept in cell biology is that enhanced degradation of cellular components through autophagy can counteract energy depletion caused by shortage of environmental nutrients. My host laboratory recently discovered that β cells employ a very distinct and so far unknown mechanism to adapt to nutrient depletion. β cells induce specific degradation of newly formed insulin granules through lysosomes and suppress autophagy upon nutrient withdrawal. Insulin granule degradation allows for generation of intracellular nutrients and in the same time avoids release of these granules. Their preliminary results suggest that lysosomal insulin granule degradation is dramatically enhanced in β cells of diabetic islets from mice and humans. This increase is accompanied by a drop in autophagy, a known protective process in the β cell. My project will fortify that impaired lysosomal activity, insulin degradation and suppressed autophagy contribute to β cell failure in T2D.
Novel Applications in 19F Magnetic Resonance Imaging (NOVA-MRI)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Spain,Spain,Germany,Italy,Norway,Netherlands,Netherlands,Netherlands,United Kingdom,United Kingdom
Call: Innovative Training Networks (H2020-MSCA-ITN-2019, 2019)
Start date: 2020-02-01
End date: 2024-01-31
Duration (months): 48.0
Total project cost (EUR): 4051634.04
EU funding (EUR): 4051634.04
Participants: 12
Project status: SIGNED

Magnetic resonance imaging (MRI) is a leading clinical diagnostic technique that is able to provide whole body imaging, and when individual cells are imaged in living animals, it can provide new insights into the biology of cell trafficking and migration. For cells to be visualised by MRI, they generally must be labelled to enable their discrimination from surrounding tissue. The development of magnetic resonance imaging (MRI) contrast agents is therefore an active area of research, where the basis for this interest is the expansion of MRI as a high-resolution and non-invasive important preclinical and clinical imaging modality. Moreover, there are now new opportunities to developing smart materials with multifunctional abilities including MRI contrast in-built within biomaterial structures, functionalisation with targeting ligands and the carrying of a therapeutic payload. This move towards a new generation of MRI contrast reagents has also been spurred on by the mounting evidence against gadolinium-based contrast agents (GBCAs). They are currently the agents of choice and were considered historically safe and well tolerated until recently. However, they have been found to accumulate in various tissues of patients who do not have renal impairment, including bone, brain and kidneys. Furthermore, in 2015, the FDA released a new safety announcement regarding GBCAs and the risk of accumulated deposits in the brain following repeated use. Whilst GBCAs are being investigated, they can still be administered but healthcare professionals have been advised to limit the use of GBCA to situations in which contrast is deemed absolutely necessary.This has opened the door to the novelty of using perfluorocarbon (19F) being incorporated inside smart nanoparticles, which can offer unique quantitative signatures for molecular MRI with no competing background signal.

Keywords: magnetic resonance imaging,nanomaterials,perfluorocarbons
Integrating torrefaction of pulp and paper industry sludge with microbial conversion: A new approach to produce bioenergy carriers and biochemicals in a view of bio and circular economy. (TOPIS-BioCirc)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Estonia
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2020-09-01
End date: 2022-08-31
Duration (months): 24.0
Total project cost (EUR): 154193.28
EU funding (EUR): 154193.28
Participants: 1
Project status: CLOSED

Pulp and paper industries (PPI) are known for producing large quantities of organic residues. Considering the economic and environmental aspects, the resource recovery from PPI wastes is necessary in order to increase the resource efficiency. In that regard, developing novel biorefinery processes to produce multiple products from PPI wastes is interesting under bio and circular economy. On the other hand, the interest on torrefied biomass is rising over the globe as it can replace the coal. However, the economics of torrefied pellets is not competitive compared to the coal. As the majority of the torrefied pellets production costs are coming from raw materials, sourcing them from low cost resources could be helpful to improve the economic competitiveness of the torrefied pellets over coal. To address the above said two issues, this project will study the feasibility of the torrefaction of pulp and paper industry sludge (PPIS) and integrating it with microbial conversion to produce bioenergy carriers i.e. bio-coal and bio-methane and volatile fatty acids. To achieve this, the expertise of the experienced researcher on biomass torrefaction, process modeling and feasibility analysis will be combined with the expertise of the supervisor on microbial conversion processes and biomass pretreatment. Initially, torrefaction of dewatered PPIS will be carried out in order to establish the biofuel characteristics of torrefied PPIS. Later, anaerobic digestion of torrefaction condensate produced through the torrefaction of PPIS will be studied at varied operating conditions in order to establish the production potential of bio-methane and volatile fatty acids. Finally, the proposed process integration will be simulated to a commercial scale from laboratory experimental results in order to evaluate the techno-economic and environmental feasibility. The proposed study can help the European society to shift toward low carbon economy and achieve sustainable development goals.

Keywords: pulp and paper industry sludge,torrefaction,anaerobic digestion,volatile fatty acids,biorefinery,circular economy,bioeconomy,nutrient recovery,digestate,techno economic analysis
The transition to a renewable electricity system and its interactions with other policy aims (TRIPOD)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Institutions, Governance and Legal Systems
Panel description: Political science, international relations, law
Countries involved: Germany,Switzerland
Call: ERC Starting Grant (ERC-2016-STG, 2016)
Start date: 2017-08-01
End date: 2023-01-31
Duration (months): 66.0
Total project cost (EUR): 1499940.0
EU funding (EUR): 1116846.12
Participants: 3
Project status: CLOSED

In order to meet its long-term climate targets, the European Union has decided to reduce its power sector carbon emissions by 93-99% by 2050. This means that Europe aims to transition to a largely, or fully, renewable power system. This is however not the only energy policy aim: besides a transition to renewables, further aims include an energy efficiency increase and demand reduction; liberalisation of the power markets and exposure of renewables to competition; and europeanisation of renewable energy policy, power grids, and the creation of a European internal power market. Here, I investigate whether and how these policies interact and affect the chances for and costs of a transition to a renewable power system; how the other aims constrain the options for renewables; and how policy conflicts can be resolved. Current policy discourse treats these policy aims either as independent or synergistic. My hypothesis is that they are not at all independent and that pursuing the aims of demand reduction, liberalisation and europeanisation strongly influences the transition to renewables, and that the aims are partially antagonistic, implying a need for trade-offs. The purpose of my research is to test these hypotheses and explore the policy synergies or antagonisms, by investigating yet under-researched aspects of the interactions. These include how reaching the other aims influences the transition dynamics; how key actors may alter their behaviour due to such other developments; and how reaching another policy aim impacts the stability of a fully renewable power system. I adopt an interdisciplinary approach, drawing on transition research, engineering, political science and economics, with each perspective adding a piece of the puzzle. The answers will contribute to both the disciplinary and the policy-driven renewable energy research, and provide insights to help policy-makers define less conflicting policies, thus supporting the European transition to renewables.

Keywords: renewable electricity,policy interactions
Using AI Computer Vision 2.0 for Visual Inspection in the Industry (MoonVision 2.0)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Austria
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2019-02-01
End date: 2019-07-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Manufacturing and other companies still rely on humans for visual inspection checks despite the high error rates. This is because automated systems are too general and too expensive and conventional machine vision is too simple. Computer vision and AI can bring the next needed revolution in digitization. They allow machines to see and understand processes in their environment. The AI computer vision platform MoonVision detects item type and amounts on a visual basis using proprietary algorithms and triggers events including the optimization of machines, payment processes or data generation. MoonVision works with a wide range of commonly available hardware and the deep learning algorithms only require a small amount of images and data to learn. MoonVision can be applied in a wide range of industries ranging from inspecting metal surfaces to tracking the types of containers in waste processing. Several renown companies are already using MoonVision including Miba, Audi, Sacher, etc. MoonVision has allowed us to enter the AI image recognition market that was valued at €1 billion in 2017. We could gain the part of the market that is dedicated to recognizing images for industrial applications. We follow an SaaS business model with different subscription levels depending on the vertical. Our customers are different companies in manufacturing, hospitality and anyone who needs visual inspection. The most important types of suppliers are hosting, computation and data suppliers. Our core team has three members. Our CEO and Founder Florian is a web developer and entrepreneur and holds an MS in Economics. The Executive Director and COO Kamil has worked in consulting since 2008 and holds a BA in business. Tatiana is our AI data engineer and holds a PhD in Optics and Musical Acoustics. Advanced technologies are currently fueling the "fourth industrial revolution," with the potential of transforming EU industries and creating enormous growth in the European economy.

Keywords: deep learning,object recommendation,scene detection,shot detection,object label recommendation
Nanomaterials in Oncology: Exploiting the Intrinsic Cancer-Specific Toxicity of Nanoparticles. (NANONC)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Belgium
Call: ERC Starting Grant (ERC-2017-STG, 2017)
Start date: 2018-01-01
End date: 2022-12-31
Duration (months): 60.0
Total project cost (EUR): 1947519.0
EU funding (EUR): 1947519.0
Participants: 1
Project status: SIGNED

In our current society, therapeutic strategies against cancer suffer from dose-limiting toxicity, lack of specificity and high morbidity. To overcome this, the use of nanomaterials (NMs) is rising, where several NM formulations are undergoing clinical trials or are used in clinics where the NMs are used as drug delivery vehicles or as mediators in physical anticancer methods (e.g. hyperthermia), where to date, the success rate is limited due to low tumor targeting efficacy, lack of specificity and frequent re-use of classical toxicity mechanisms. To overcome these issues, this research program aims to exploit the intrinsic toxicity of certain types of metal-based, degradation-prone NMs (Fe-doped ZnO, Fe-doped CuO and Ag of different sizes and coatings) towards only cancer cells as a novel and generic anti-cancer tool with 1) improved efficacy against difficult to treat cancers such as multidrug-resistant cancer cells, 2) enhanced specificity and selectivity of the treatment by the intrinsic cancer cell-specific toxicity of NMs towards cancer cells. To overcome the issues related to selective delivery of the NMs, tumor-homing cells will be used that have been shown to efficiently home to primary tumors and their metastases. In practice, the NMs used show distinct degradation kinetics that primarily induce cancer-selective toxicity. To obtain efficient tumor targeting, suicide gene-expressing tumor-homing cells will be loaded with the NMs in their cytoplasm, hereby impeding premature NM degradation. The tumor homing efficacy of these cells will be monitored via optical imaging and once at the target site these cells will be chemically destroyed using the suicide gene strategy. This will release the NMs into the tumor site, where they can selectively destroy the cancer cells. This research program will be the first to explore the full potential of cancer-specific toxicity of NMs and the use of cytoplasmic loading of cells as biological carriers for efficient delivery.

Keywords: nanomedicine,nanoparticles,nanotoxicology